EN DE
Watch Oruka Therapeutics, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Oruka Therapeutics, Inc. (ORKA) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Oruka Therapeutics, Inc. stock $73.03, price $110, that is 33.3% below the price, quality 24 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

OT Oruka Therapeutics, Inc. logo Thin data Nov 11, 2026

Oruka Therapeutics, Inc.

ORKA · US
Expensive, weak quality

Our calculation puts a fair price 33% below what the stock costs today.

Mixed Growth (revenue YoY +1105.3 %/yr in USD)
Mixed vs. peers (4/7)
Insiders sold $337.6M (6M)
Fair value $73.03 · Overvalued
Quality 24/100
Negative free cash flow
Narrow moat 8/100 · thin data
Negative coverage
Thin data
Estimate
Watch Oruka Therapeutics, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$113.08 $6.78 Fair Value $73.03 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $6.78 – $113.08 · fair‑value band $54.77 – $91.29 · the $109.50 price screens above the $73.03 fair value. As of Nov 11, 2026.

Follow Oruka Therapeutics in your weekly email

Every Wednesday you see whether Oruka Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Show moreShow less

Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.

The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Stock analysis

Oruka Therapeutics, Inc. (ORKA) currently trades at $109.50, while our estimate is $73.03, 33% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $54.77 (bear) to $91.29 (bull), the price of $109.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Oruka Therapeutics, Inc. reported revenue of $0 in FY2025 versus $545K in FY2005. Reported net income was −$105M in FY2025.

Key figures

Market cap $6.9B Mid · EPS (TTM) $−2.08 · Return on equity −18.2% · Return on assets (EBIT) −24.9% (5-year average) · Free cash flow −$88.4M · Net cash $45.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 3% below its 52-week high and 315% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −33%, ORKA screens richer than that median.

Fair Value

Bear $54.77 Fair Value $73.03 Bull $91.29
Price $109.50 · Downside -33.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 24/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 15
Are margins and returns getting better?
Cashflow 22
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 84
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 98
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 7 officers or directors sold shares worth $337.6M and none bought.

  • SaleLawrence Otto KleinChief Executive Officer, Director6× since Mar 16, 2026: 130,910 shares, avg. $90.10$11.8MNov 2, 2026
  • SalePaul T QuinlanGeneral Counsel6× since Mar 16, 2026: 73,505 shares, avg. $101.56$7.5MOct 20, 2026
  • SaleJoana GoncalvesChief Medical Officer11× since Dec 19, 2025: 79,535 shares, avg. $63.71$5.1MOct 15, 202610b5-1 plan
  • SaleArjun AgarwalSenior Vice President, Finance9× since Mar 16, 2026: 62,676 shares, avg. $81.93$5.1MOct 12, 2026
  • SaleLaura Lee SandlerChief Operating Officer8× since Jan 2, 2026: 35,106 shares, avg. $55.33$1.9MSep 15, 2026
  • SaleTomas KiselakDirector, 10% owner3,553,410 shares at $84.43$300.0MJul 1, 2026
  • SaleCarl DambkowskiDirector2× since May 21, 2026: 140,000 shares, avg. $61.75$8.6MJun 12, 202610b5-1 plan

Plus 23 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ORKA screens overvalued: fair value 33% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (76 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Negative
Recent news coverage is more negative than average.

Compare Oruka Therapeutics, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside −33.3% · Below median
Profitability
Return on assets −21.6% · Above median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 14.59× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs ORKA
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs ORKA
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs ORKA
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs ORKA
argenx SE ARGX $971.55 $908.40 −7% vs ORKA
CSL Limited CSL A$201.68 A$181.40 −10% vs ORKA
Moderna, Inc MRNA $250.83 $158.70 −37% vs ORKA
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs ORKA
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs ORKA
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs ORKA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Oruka Therapeutics, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Oruka Therapeutics, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/ORKA

Frequently asked questions

Is Oruka Therapeutics, Inc. (ORKA) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $73.03 versus a price of $109.50, about 33% lower (overvalued).
What is the fair value of ORKA?
Our estimate for Oruka Therapeutics, Inc. is $73.03 (as of Nov 11, 2026), built from audited fundamentals. The current price: $109.50.
What is the quality score of ORKA?
Oruka Therapeutics, Inc. has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oruka Therapeutics, Inc. (ORKA)?
Our calculated price target is the estimate of $73.03 (as of Nov 11, 2026). Cautious scenario $54.77, optimistic scenario $91.29. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Oruka Therapeutics, Inc. stock forecast for 2026?
Our estimate puts fair value at $73.03, about 33% lower versus a price of $109.50 (overvalued). Cautious scenario $54.77, optimistic scenario $91.29. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Oruka Therapeutics, Inc. (ORKA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oruka Therapeutics, Inc. it is $73.03 per share (as of Nov 11, 2026), against a price of $109.50.
Is Oruka Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of Nov 11, 2026, ORKA trades above its calculated fair value: price $109.50, fair value $73.03, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ORKA?
No. The price is what the market pays today ($109.50); the fair value is what the company's own numbers justify ($73.03). For Oruka Therapeutics, Inc. the two are $36.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oruka Therapeutics, Inc. worth?
The market values Oruka Therapeutics, Inc. at about $6.9B (market capitalisation, as of Nov 11, 2026). Per share that is $109.50; our models calculate a fair value of $73.03 per share.
What do the bullish and bearish scenarios say about ORKA?
Our models span a range for Oruka Therapeutics, Inc.: cautious scenario $54.77, base $73.03, optimistic $91.29 per share (as of Nov 11, 2026, price $109.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oruka Therapeutics, Inc. (ORKA)?
Balance-sheet figures for Oruka Therapeutics, Inc. (as of Nov 11, 2026): return on equity −18.2%. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is ORKA from its 52-week high?
Oruka Therapeutics, Inc. trades at $109.50, about 3% below its 52-week high of $113.08 and 315% above the low of $26.38 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $73.03 is for.
Which stocks are comparable to Oruka Therapeutics, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oruka Therapeutics, Inc. stock attractive at the current price?
The data as of Nov 11, 2026: price $109.50, calculated fair value $73.03 (−33%), Quality Score 24/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Oruka Therapeutics, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oruka Therapeutics, Inc. (ORKA)?
The closing price on Nov 10, 2026 was $109.50. Our estimate is $73.03, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oruka Therapeutics, Inc. right now?
The price sits above even our optimistic bull case ($91.29). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Oruka Therapeutics, Inc.

How large is the market capitalisation of Oruka Therapeutics, Inc. (ORKA)?
The market capitalisation of Oruka Therapeutics, Inc. is $6.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Oruka Therapeutics, Inc. (ORKA)?
Earnings per share at Oruka Therapeutics, Inc. are $−2.08. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Oruka Therapeutics, Inc. (ORKA)?
The return on equity (ROE) of Oruka Therapeutics, Inc. is −18.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oruka Therapeutics, Inc. (ORKA)?
On an EBIT basis the return on assets of Oruka Therapeutics, Inc. is −24.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Oruka Therapeutics, Inc. (ORKA) generate?
The free cash flow of Oruka Therapeutics, Inc. is −$88.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Oruka Therapeutics, Inc. (ORKA) hold?
Oruka Therapeutics, Inc. holds more cash than debt, $45.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Oruka Therapeutics, Inc. in the live analysis

One click puts Oruka Therapeutics, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.